ArticleRespirology (Carlton, Vic.)2026
Diagnostic Yield of EBUS Mediastinal Cryobiopsy Versus TBNA in Suspected Lymphoproliferative Disorders: A Prospective Multicentre Study.
Article in Respirology (Carlton, Vic.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transbronchial Mediastinal Cryobiopsy-Rising to the Challenge.Respirology (Carlton, Vic.) · 2026Article
- Diagnostic Yield of EBUS Mediastinal Cryobiopsy Versus TBNA in Suspected Lymphoproliferative Disorders: A Prospective Multicentre Study.Respirology (Carlton, Vic.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe diagnosis of mediastinal lymphoproliferative disorders (LPDs) is often challenging and requires histopathological assessment from large tissue samples. As a result, new diagnostic techniques have been introduced alongside the commonly used endobronchial ultrasound-guided trans-bronchial needle aspiration (EBUS-TBNA). Among them, EBUS-guided transbronchial mediastinal cryobiopsy (EBUS-TBMC) has shown promising potential, although high-quality evidence remains limited. The aim of the study was to assess the diagnostic yield of EBUS-TBMC compared with EBUS-TBNA in patients with suspected mediastinal LPDs.
methodsThis prospective multicentre study enrolled patients with suspected mediastinal LPDs undergoing bronchoscopy with EBUS for mediastinal lymph node sampling. All participants had either B symptoms or a history of LPD. All patients underwent EBUS-TBNA followed by EBUS-TBMC from the same mediastinal lymph node. Final diagnoses were confirmed after a 6-month follow-up.
resultsFifty-eight patients underwent EBUS, of whom 50 completed both EBUS-TBNA and EBUS-TBMC. There were eight cases of failed EBUS-TBMC who were not included in the analysis. The most frequent diagnoses were LPDs (54%) and sarcoidosis (30%). EBUS-TBNA and EBUS-TBMC had overall diagnostic yield of 52% and 80%, respectively. Among non-diagnostic EBUS-TBNA samples, 80% were diagnostic with EBUS-TBMC (odds ratio 4.89, 95% CI 1.76-13.6). For confirmed LPDs, diagnostic yield was 41% for EBUS-TBNA and 85% for EBUS-TBMC. No major complications during or following the EBUS-TBMC were observed.
conclusionEBUS-TBMC was superior to EBUS-TBNA and achieved a high diagnostic yield in patients with suspected mediastinal LPDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.